Deal Statistics Quarterly, Q3 2004
Executive Summary
In this issue, we present another installment of our quarterly review of dealmaking-for July-September 2004. Our data comes from Windhover's Strategic Transactions Database, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics industries.
You may also be interested in...
CooperVision and Ocular Sciences: Stronger as One
Economies of scale and product breadth were behind the $1.2 billion merger of contact lens companies the Cooper Companies and Ocular Sciences. The combined company will be better positioned to benefit from the three drivers in the rapidly growing $6 billion worldwide contact lens market: the bulge in the youth population known as Echo Boomers; an increasing mix of advanced, premium priced products, and the worldwide increase of myopia.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.